Recent advances in drug delivery and targeting to the brain

Bharti Sethi, Virender Kumar, Kalika Mahato, Donald W. Coulter, Ram I. Mahato

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Our body keeps separating the toxic chemicals in the blood from the brain. A significant number of drugs do not enter the central nervous system (CNS) due to the blood-brain barrier (BBB). Certain diseases, such as tumor growth and stroke, are known to increase the permeability of the BBB. However, the heterogeneity of this permeation makes it difficult and unpredictable to transport drugs to the brain. In recent years, research has been directed toward increasing drug penetration inside the brain, and nanomedicine has emerged as a promising approach. Active targeting requires one or more specific ligands on the surface of nanoparticles (NPs), which brain endothelial cells (ECs) recognize, allowing controlled drug delivery compared to conventional targeting strategies. This review highlights the mechanistic insights about different cell types contributing to the development and maintenance of the BBB and summarizes the recent advancement in brain-specific NPs for different pathological conditions. Furthermore, fundamental properties of brain-targeted NPs will be discussed, and the standard lesion features classified by neurological pathology are summarized.

Original languageEnglish (US)
Pages (from-to)668-687
Number of pages20
JournalJournal of Controlled Release
Volume350
DOIs
StatePublished - Oct 2022

Keywords

  • Blood-brain barrier
  • Brain cancer
  • Glioblastoma
  • Medulloblastoma
  • Nanomedicine

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Recent advances in drug delivery and targeting to the brain'. Together they form a unique fingerprint.

Cite this